Researchers found that patients with higher HtrA1 levels responded better to chemotherapy, while lower levels were associated with resistance. The study suggests HtrA1 mediates cancer cell killing and loss of HtrA1 contributes to chemotherapy resistance.
A new three-drug regimen combining Taxotere with standard chemotherapy reduces mortality by nearly 30 percent in patients with squamous cell carcinoma of the head and neck. The study, conducted at Dana-Farber Cancer Institute, showed improved survival rates with this treatment approach.
Researchers found that when treatment was restarted after a chemotherapy holiday, roughly three-quarters of study subjects responded again or experienced stabilized PSA levels. The median duration of the first chemotherapy holiday was 16 weeks, providing a clinically meaningful break for most patients.
A new clinical trial called TAILORx aims to determine whether chemotherapy is necessary for women with early-stage breast cancer. The study will use OncotypeDXTM, a genetic test that estimates a patient's risk of recurrence and predicts treatment outcomes.
A study found that 17% of patients with non-small cell lung cancer experienced a significant change in tumor size after just 31 days of chemotherapy. Tumors either grew or shrunk by 20-48% during this period, prompting changes to treatment plans.
A new study analyzed data from 3,193 stage III colon cancer patients and found that 78.2% completed adjuvant chemotherapy treatment. Incomplete treatment was linked to physical frailty, treatment complications, and lack of social support.
Researchers recommend pre-screening to avoid worst liver damage caused by chemotherapy drugs. The study found that irinotecan was associated with steatohepatitis and oxaliplatin with sinusoidal dilation, which can lead to liver disease and failure.
Researchers create computer algorithms to verify connection between material delivery and fluid pressure, potentially increasing chemotherapy success rate. The method may be used before chemotherapy begins to determine if high fluid pressure could render treatment ineffective.
Researchers developed a chemotherapy gel that slowly releases doxorubicin to kill remaining cancer cells, eradicating tumors in mice. The treatment also reduces breast deformity by filling dimples and indentations after surgery.
Research reveals chemotherapy works better for ER-negative tumors, with significant survival benefits, while tamoxifen is effective but less impactful for ER-positive tumors. Modern chemotherapy regimens show promise for treating ER-negative patients.
Researchers found significant improvements in disease-free survival and overall survival rates for patients with ER-negative breast cancer treated with modern chemotherapy regimens. These findings underscore the need for tailored treatments based on tumor subtypes.
A six-month walking exercise program may help alleviate cognitive impairment in cancer survivors. Researchers aim to identify new tactics to improve quality of life for those affected by chemotherapy-induced memory problems.
A research group identified 679 genes differently expressed in responders to chemotherapy compared to non-responders. RT-PCR analysis validated the findings, confirming the differential expression of 22 genes. The study suggests integrating molecular networks could improve diagnosis and treatment of colorectal cancer.
Researchers found that hepatic arterial infusion (HAI) therapy extended survival and improved quality of life in patients with colorectal cancer that has spread to the liver. HAI therapy resulted in a median survival of 24 months, better response rates, and longer time to disease progression compared to systemic chemotherapy.
Parallel administration of chemotherapy and darbepoetin alfa every 3 weeks is safe and effective in treating anemia. Gene expression profiling may provide more accurate information for certain high-risk breast cancers than laboratory examination alone.
A randomized controlled study found that pretreating patients with hepatocellular carcinoma (HCC) undergoing chemotherapy with lamivudine significantly reduces the risk of Hepatitis B reactivation and severe hepatitis. The study identified a lower viral load threshold as a better predictor of relapse.
The National Cancer Institute has issued a clinical announcement recommending a combination of chemotherapy regimens for women with advanced ovarian cancer. The treatment involves delivering chemotherapy directly into the abdominal cavity (intraperitoneal, or IP) in addition to traditional IV chemotherapy. This approach appears to be m...
A New England Journal of Medicine study found that women who received intraperitoneal chemotherapy had a median survival time 16 months longer than those receiving IV chemotherapy alone. The importance of referral to physicians with expertise in surgical management of ovarian cancer is highlighted.
A new study confirms the survival benefit of intra-abdominal chemotherapy, also known as intraperitoneal (IP) chemotherapy, for most women with advanced ovarian cancer. The treatment has shown an overall survival period of approximately one year after optimal debulking surgery.
A seven-year study of over 400 patients found that delivering chemotherapy directly into the abdomen via a catheter increases survival and relapse-free survival rates compared to intravenous chemotherapy alone. However, side effects are significantly worse for the abdominal group.
A Phase 3 study found that Aranesp treatment achieved and maintained target hemoglobin levels, reducing red blood cell transfusions by 24%. The extended dosing schedule may allow physicians to treat anemia on the same schedule as chemotherapy.
A pilot study found that pairing low-dose chemotherapy with the anti-VEGF antibody bevacizumab delayed breast cancer progression by an average of 5.5 months compared to low-dose chemotherapy alone. The combination therapy showed better results, with 29% partial responses and 41% stable disease.
The use of chemotherapy after surgery for stage III colon cancer has increased, leading to improved 5-year survival rates. Adjuvant chemotherapy benefits younger and elderly patients equally, while black patients with high-grade cancers see less significant improvements.
Chemotherapy has been shown to improve survival rates for patients with advanced colon cancer, regardless of age or sex. The study found that women and the elderly received the same benefit as younger adults, but were less likely to receive chemotherapy treatment.
Researchers found that chemotherapy with doxorubicin and cisplatin extended disease-free survival by 50% and overall survival by 13% compared to radiation therapy. Serious side effects were more common in the chemotherapy group, but a new regimen may be less toxic.
Researchers at U-M found that focused radiation combined with chemotherapy significantly improves survival rates for liver cancer patients. The new method delivers an intensive punch directly to tumors while limiting exposure to normal tissue.
Researchers developed a genetic profile of ovarian cancer that predicts survival and identifies key genes involved in chemotherapy response. The study used microarray analysis to identify a gene expression profile known as the Chemotherapy Response Profile, which confirms the importance of genes such as BAX.
A new study found that a vitamin D pill combination extended the lives of men with advanced prostate cancer by about eight months compared to those receiving chemotherapy and placebo. The pill, DN-101, also protected against major side effects of chemotherapy.
Researchers found that early vaccination with pneumococcus and T-cell vaccine can rebuild immunity in cancer patients after chemotherapy, with protection developing within a month. This study paves the way for personalized therapy using engineered T-cells to boost the immune system against tumors.
A Columbia University study reveals that black women with early-stage breast cancer are two times more likely to die within five years after diagnosis compared to white women. The study found that only 68% of black patients completed all prescribed chemotherapy cycles, compared to 76% of white patients.
Mayo Clinic's new treatment protocol combining radiation therapy, chemotherapy, and liver transplantation has significantly improved the five-year survival rate for patients with bile duct cancer to 82%. The treatment enables surgeons to remove the entire liver and obtain better tumor clearance.
Researchers at Thomas Jefferson University found that giving chemotherapy and radiation together from the start may help patients with locally advanced lung cancer live longer. The study compared three treatment approaches and showed that combining chemotherapy and radiation improved patient outcomes.
Research finds that neutropenia, a type of hematological toxicity, is associated with increased overall survival in patients with advanced non-small cell lung cancer. Prospective trials are needed to assess whether drug dosing guided by toxic effects could improve chemotherapy efficacy.
A recent study has found that obese patients with estrogen-receptor negative (ER-negative) breast cancer are at risk of undertreatment due to reduced chemotherapy doses. The study, published in The Lancet, suggests that obese women with ER-negative disease who receive 85% or more of the recommended first course dose have significantly ...
Researchers identified 57 predictor genes that can accurately predict breast cancer patients' response to chemotherapy, offering a powerful tool for personalized treatment. These genetic markers can identify patients most likely to benefit from chemotherapy, potentially shifting focus away from standard treatments.
A randomised trial found that blood stem cell transplant improved disease-free survival in children with high-risk acute lymphoblastic leukaemia, compared to chemotherapy. The study showed a significant gap between the two strategies as patient risk profiles worsened.
Researchers found that the revised TNM staging system is strongly associated with disease-free survival and overall survival. The new system provides more accurate information about tumor response to chemotherapy, helping doctors determine the best treatment plan for patients.
A new study suggests that PET imaging can identify which breast cancer patients are likely to respond to chemotherapy, allowing for more effective treatment and improved patient outcomes. This breakthrough could lead to the development of personalized treatment plans, giving patients and doctors more options.
Researchers from Munich discovered that sequential FDG-PET can identify responding tumors after just one cycle of chemotherapy, allowing for earlier assessment of treatment efficacy. This could lead to more accurate individualized treatment and improved patient outcomes.
Researchers found that a vaccine targeting TRP-2 improves chemotherapy sensitivity in brain tumors. The study showed significant improvements in patient survival and tumor response rates compared to conventional treatments.
Researchers studied the combination of S-1, a new drug, and cisplatin in patients with advanced gastric cancer. Overall, 65% of patients responded to the chemotherapy, showing tumors shrunk in response to the drug.
A Phase 3 study of Aranesp dosed every three weeks achieved a 91% success rate in maintaining target hemoglobin levels, with 72% of patients sustaining the level over 16 weeks. The treatment showed reduced need for red blood cell transfusions and consistent adverse event profile.
Researchers found that using limited amounts of chemotherapy improved outcomes in 86.4% of patients and overall survival rates of 95.9%. Factors such as bone marrow count and extra chromosomes were key predictors of response to less intensive treatment.
A new study demonstrates high rates of tumor death in patients receiving a preoperative chemotherapy and radiation regimen, suggesting a promising approach for treating high-grade soft tissue sarcomas. The regimen has been associated with significant but manageable toxicity and modest wound complication rates.
A landmark Phase III trial found that concurrent chemotherapy and radiation therapy followed by surgery significantly improves lung cancer patient survival. Five-year survival rates were 36% for patients with partial lung removal and 27% for those who underwent concurrent treatment.
A study at the American Society of Clinical Oncology meeting found that a targeted cancer drug combined with low-dose chemotherapy shrinks ovarian cancer tumors in nearly half of patients. The treatment also slows disease progression and achieves stable disease in 59% of patients.
A large community-based clinical trial showed a significant reduction in febrile neutropenia and chemotherapy dose reductions among older patients receiving Neulasta. The study found that Neulasta reduced the incidence of serious adverse events, including hospitalizations and pneumonia.
Researchers at Vanderbilt University Medical Center found that adding bevacizumab to standard chemotherapy extended median survival by 2.3 months, improving overall tumor response rates and progression-free survival. This new treatment regimen is recommended as the standard for advanced non-small cell lung cancer patients.
A large collaborative analysis of early breast cancer trials found that standard treatments such as chemotherapy and hormonal therapy can halve the 15-year risk of death from breast cancer. The study included data from 145,000 women with early breast cancer in 194 randomised trials.
A study published in the Journal of Clinical Investigation has identified a new protein called SPARC that plays a crucial role in tumor therapy resistance. The researchers found that restoring SPARC expression in resistant cells improved their sensitivity to chemotherapy, suggesting potential therapeutic applications.
Researchers found that combining chemotherapy with Herceptin before surgery in early-stage breast cancer patients resulted in a 42% higher tumor reduction and 66.7% pathological complete remission rate compared to chemotherapy alone. The combination also showed less risk of heart damage, leading the clinical trial to be halted early.
A new study finds that MRI is more accurate than current standards in assessing the effectiveness of neoadjuvant chemotherapy for breast cancer. The imaging technique correctly identified the presence of residual tumor in 71% of cases, while sonography and clinical examination were less accurate.
A study analyzing data from four clinical trials found that older patients with lymph node-positive breast cancer can tolerate standard and intensive chemotherapy regimens similarly to younger patients. The findings suggest that age is not a barrier to the effectiveness of adjuvant chemotherapy in healthy older women.
The addition of locoregional radiation therapy significantly improved breast cancer survival and reduced mortality in high-risk patients. A 20-year follow-up study found that the regimen resulted in a 32% reduction in breast cancer mortality and a 27% reduction in overall mortality compared to chemotherapy alone.
Researchers at City of Hope Cancer Center have successfully treated 17 out of 20 HIV-positive patients with refractory lymphoma using high-dose chemotherapy and autologous stem cell rescue. The study shows promising results with an 85% survival rate, paving the way for further investigation into this potential cure.
Researchers found women with invasive lobular carcinoma have a different disease type, benefiting from tailored treatment approaches. Alternative therapies like hormonal treatments may be more effective for this rare form of breast cancer.
A new molecular test uses a panel of genes to predict the risk of breast cancer recurrence and identify patients who will benefit from chemotherapy. The test shows that women with low risk of recurrence do not derive much benefit from chemotherapy, while those with high risk have a large benefit.
A recent re-analysis of large clinical trials found that chemotherapy significantly improves survival rates in patients with ER-negative tumors, reducing the risk of death by 56 percent. The study suggests that chemotherapy has a greater impact on ER-negative patients than previously thought.
Researchers found that patients with basal-like and erbb2+ subgroups had the highest rates of pathological complete response to chemotherapy, while luminal tumors showed minimal response. The study suggests stratifying patients into molecular subgroups for more accurate treatment predictions.
BRCA1 mutations are found in only 5% of breast and ovarian cancers, but loss-of-function mutations can significantly increase cancer risk. Researchers review preclinical and clinical evidence to determine if BRCA1 function can predict chemotherapy response, highlighting the need for prospective studies.